Work

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

Year: 2016

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw676

Authors: E. Jonasch, E. Hasanov, P.G. Corn, T. Moss, K.R. Shaw, S. Stovall, V. Marcott, B. Gan, S. Bird, X. Wang, K.A. Do, P.F. Altamirano, A.J. Zurita, L.A. Doyle, P.N. Lara, N.M. Tannir

Institutions: The University of Texas MD Anderson Cancer Center, National Institutes of Health, National Cancer Institute, UC Davis Comprehensive Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute

Awards: G3565137481, Mechanistic studies of cancer cell adaptive response to PI3K/AKT inhibition, G9000034222

OpenAlex ID: W2561417850

FWCI: 4.767

Cites: 24

Cited by: 45

Related to: 10